Female Stress Urinary Incontinence Treatment Devices Market Size, Share, and Analysis, By Product Type (Urethral Slings, Catheters, Vaginal Pessaries, and Others), By End-user (Hospitals & ASCs, Specialty Clinics, and Others), and Regional Forecast till 2032

Female stress urinary incontinence treatment devices are used to treat sudden, involuntary urine loss due to increased abdominal pressure, affecting the patient’s quality of life. Stress urinary incontinence occurs in females during the activities of coughing, laughing, sneezing, straining, or exercising. Loss of support from pelvic floor muscles and connective tissues leads to this condition. Some of the factors resulting in the condition include chronic cough, obesity, trauma after vaginal delivery, pregnancy, menopause, constipation, smoking, and heavy lifting exercises.

The initial complaints of females suffering from stress urinary incontinence are urgency, frequency, and dysuria. The increasing disease prevalence in women and disruptions to their quality of life contribute to the growing need for female stress urinary incontinence treatment devices.

• According to data published by the National Institute of Health in June 2023, 15.7% of adult women are affected by stress urinary incontinence in the U.S., around 77.5% have troublesome symptoms, and 28.8% report having moderate to severe symptoms.

This rise in the number of incidences leads to an increase in the adoption of female stress urinary incontinence treatment devices. Furthermore, a rise in product launches focused on non-invasive treatments is expected to fuel the market growth.

• For instance, in February 2020, Atlantic Therapeutics (INNOVO) announced the U.S. FDA approval for over-the-counter sales of its non-invasive, clinically proven wearable device, Innovo. Females use it with stress urinary incontinence to treat the root cause of bladder weakness. Previously, the product was available through prescription in the U.S.

Moreover, an increase in the research and development activities for developing new technologically advanced devices for female stress urinary incontinence treatment propels the market expansion.

Impact of COVID-19 on the Female Stress Urinary Incontinence Treatment Devices Market

The COVID-19 pandemic had a slightly negative impact on the female stress urinary incontinence treatment devices market in 2020. The pandemic shifted the healthcare priorities toward managing COVID-19 cases, leading to a reduced focus on elective procedures and non-life-threatening conditions. This shift affected the demand for devices used for female stress urinary incontinence treatment.

• For instance, in February 2021, the National Institute of Health reviewed the impact of the pandemic on urogynecology patients. The survey report states that continence surgery was suspended as medical therapies were recommended as first-line treatment options for female urinary incontinence via virtual or remote clinics.

Additionally, a decrease in patient visits to hospitals and disruptions in manufacturing supply chains globally affected the production and distribution of the devices, leading to a decreasing adoption of stress urinary incontinence treatment devices.

Furthermore, as healthcare systems adjusted to challenges created by the pandemic, there was a slow increase in utilization of devices for treating female stress urinary incontinence in 2021. The market was fully normalized in 2022.

In addition, industry players are concentrating on bringing new devices to the market after the pandemic. This is expected to boost market growth during the forecast period, 2024-2030.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Urinary Incontinence in Females, By Key Country/Region, 2022


• Technological Advancements


• Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)


• Impact of COVID-19 on the Market

Analysis by Product Type

Based on product type, the female stress urinary incontinence treatment devices market is segmented into urethral slings, catheters, vaginal pessaries, and others.

The urethral slings segment accounted for a significant share of the global market in 2023. The urethral slings have become popular due to their high efficiency in controlling urine leakage, versatility, and ability to provide long-lasting relief from stress incontinence symptoms. Moreover, urethral slings have lower risks of complications compared to other surgical interventions for stress incontinence and are recommended by women's healthcare organizations.

• According to the data published in the International Federation of Gynecology and Obstetrics (FIGO) in February 2023, the new recommendations published by FIGO on Urogynecology and Pelvic Floor Disorders, the use of mid-urethral slings are considered safe and efficient for the treatment of stress urinary incontinence in females.

Furthermore, compared to other surgical procedures, urethral sling placement is less invasive, leading to shorter recovery times and reduced postoperative pain. These factors lead to the increasing adoption of urethral slings, driving the growth of the market during the forecast period.

Regional Analysis

North America dominated the female stress urinary incontinence treatment devices market in 2023 and is expected to maintain its position over the forecast period. The region dominated the market due to an increase in the prevalence of stress incontinence among adult females. Additionally, the region has significant advancements in healthcare technology and innovation, leading to the development of advanced treatment devices.

• For instance, in July 2023, UroMems, a prominent company for developing innovative technologies to treat stress urinary incontinence, announced its successful completion of the first-ever implantable automated artificial sphincter, UroActive smart, for the treatment of female stress urinary incontinence.

Additionally, a high level of awareness among healthcare professionals and patients regarding the condition and the availability of various treatment measures increases the adoption of these devices in the region.

Furthermore, in the North America region, the growth of the market for female stress urinary incontinence treatment devices is propelled by advanced infrastructure, substantial healthcare spending, a favorable regulatory environment, and robust research and development initiatives.

Key Players Covered

The report includes the profiles of key players such as Medical Device Business Services, Inc. (Johnson &Johnson MedTech), Caldera Medical, Inc., BD, B. Braun Medical Ltd, CooperSurgical Inc., MEDGYN PRODUCTS, INC., Boston Scientific Corporation, Atlantic Therapeutics (INNOVO), Coloplast Corp, Convatec Inc., and other prominent players.

Key Industry Developments

• In January 2024, Boston Scientific Corporation acquired Axonics, Inc. and entered a firm agreement to strengthen its product portfolio with Axonics, Inc.’s minimally invasive sacral neuromodulation (SNM) therapy to treat overactive bladder and to serve patients with chronic conditions.


• In September 2023, Caldera Medical, Inc. announced the completion of the acquisition of Atlantic Therapeutics to add Atlantic’s FDA-cleared Innovo device to its current product portfolio for female stress urinary incontinence treatment.


• In May 2022, Convatec Inc. announced its investment of USD 30.0 million in BlueWind Medical, Ltd., to develop an implantable tibial neuromodulation device, RENOVA iStim, to treat urinary incontinence in females with urinary urgency and frequency.


• In December 2021, Caldera Medical, Inc. announced the clearance of its easy-to-use new device Desara TVez for female stress urinary incontinence by the U.S. Food and Drug Administration. Desara TVez is expanding the Desara product portfolio of the company.